ArticleNature cancer2021
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.
- Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.Frontiers in immunology · 2025Pooled it
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer.The Journal of biological chemistry · 2026Article
- Reprogramming Autophagy to Strengthen Antitumour Immunity: Advances in Immunotherapeutic Strategies.Immunology · 2026Review
- Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics.Apoptosis : an international journal on programmed cell death · 2026Review
- ULK1-driven autophagy modulation alters tumor-promoting pathways in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Article
- α-Ketoglutarate dictates AMPK protein synthesis for energy sensing in human cancers.Nature chemical biology · 2026Article
- Review
- Article
- A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer.Theranostics · 2026Article
- Targeting autophagy in dysfunctional tumor vasculature.iScience · 2025Review
- Immune checkpoint inhibitor resistance in non-small cell lung cancer: limits of vascular endothelial growth factor inhibition and new directions.Journal of thoracic disease · 2025Article
- Attack cancer: Through autophagic modulations as suppressor or promoter.World journal of clinical oncology · 2025Review
- Treatment of NSCLC after chemoimmunotherapy - are we making headway?Nature reviews. Clinical oncology · 2025Review
- Targeting autophagy to enhance cancer immunotherapy: emerging mechanisms and strategies.Medical oncology (Northwood, London, England) · 2025Review
- TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Cancer research · 2025Article
- Turning cold tumors into hot tumors to ignite immunotherapy.Molecular cancer · 2025Review
- High-dose ascorbic acid selectively induces pyroptosis in LKB1-deficient lung cancer and sensitizes immunotherapy.Cell reports. Medicine · 2025Article
- Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy.Science advances · 2025Article
- Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance.Trends in pharmacological sciences · 2025Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
38 authors at 9 institutions in 1 country.
Jiehui DengDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Aatish ThennavanLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Igor DolgalevLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, NY, USA.ORCID http://orcid.org/0000-0003-4451-126X
Ting ChenDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-1725-7956
Jie LiLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2400-9790
Antonio MarzioLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, NY, USA.
John T PoirierMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9795-5644
David H PengDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Mirna BulatovicDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Subhadip MukhopadhyayDepartment of Radiation Oncology, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Heather SilverDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Eleni PapadopoulosDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Val PyonDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Cassandra ThakurdinDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Han HanDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Fei LiDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Shuai LiDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Hailin DingDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Hai HuDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Yuanwang PanDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Vajira WeerasekaraCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Baishan JiangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6796-9500
Eric S WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ian AhearnDepartment of Medicine, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Mark PhilipsDepartment of Medicine, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-1179-8156
Thales PapagiannakopoulosLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, NY, USA.
Aristotelis TsirigosLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, NY, USA.ORCID http://orcid.org/0000-0002-7512-8477
Eli RothenbergDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-1382-1380
Justin GainorCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8697-4081
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7210-5616
Charles M RudinMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5204-3465
Nathanael S GrayDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-5354-7403
Peter S HammermanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Michele PaganoLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, NY, USA.ORCID http://orcid.org/0000-0003-3210-2442
John V HeymachDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9068-8942
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9827-2247
Nabeel BardeesyCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3867-0416
Kwok-Kin WongDivision of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA. Kwok-Kin.Wong@nyulangone.org.ORCID http://orcid.org/0000-0001-6323-235X
NYU Langone Health · USHarvard University · USNew York University · USMemorial Sloan Kettering Cancer Center · USUniversity of North Carolina at Chapel Hill · USHoward Hughes Medical Institute · USMassachusetts General Hospital · USStanford University · USThe University of Texas MD Anderson Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MTissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY · 1992 to 2026
$59.3MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MTRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MF-Box Proteins: Deregulated Cell Cycle Control and Proteolysis in CancerR01CA076584 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAGANO, MICHELE · 1998 to 2021
$4.5MMUC1-C is a Target for Reversing Immune Evasion and Resistance to ImmunotherapiesU01CA233084 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2018 to 2022
$4.1MTargeting novel therapeutic vulnerabilities in LKB1 mutant tumors.R01CA219670 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL, WONG, KWOK KIN · 2018 to 2022
$3.4MTherapeutic approaches for LKB1-deficient non-small cell lung cancerR01CA205150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2016 to 2020
$3.0MFunctions of the LKB1 tumor suppressor in control in metabolism and epigenticsR01CA215498 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL · 2018 to 2022
$2.7MNCI NIH HHS P01 CA117969NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA076584NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA205150NCI NIH HHS R01 CA215498NCI NIH HHS R01 CA219670NCI NIH HHS T32 CA009161NCI NIH HHS U01 CA233084
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsAntigen PresentationAutophagy-Related Protein-1 HomologHumansIntracellular Signaling Peptides and ProteinsAutophagy-Related Protein-1 HomologIntracellular Signaling Peptides and ProteinsULK1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.